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Abstract. Limitless replicative potential is one of the hallmarks 
of cancer that is mainly due to the activity of telomerase. This 
holoenzyme maintains telomere length, adding TTAGGG 
repetitions at the end of chromosomes in each cell division. 
In addition to this function, there are extratelomeric roles of 
telomerase that are involved in cancer promoting events. It 
has been demonstrated that TERT, the catalytic component 
of telomerase, acts as a transcriptional modulator in many 
signaling pathways. Taking into account this evidence and 
our experience on the study of azidothymidine (AZT) as an 
inhibitor of telomerase activity, the present study analyzes the 
effect of AZT on some telomeric and extratelomeric activities. 
To carry out the present study, we evaluated the transcription 
of genes that are modulated by the Wnt/β-catenin pathway, 
such as c-Myc and cyclin-D1 (Cyc-D1) and cell processes 
related with their expression, such as, proliferation, modifica-
tions of the actin cytoskeleton, cell migration and cell cycle 
in a mammary carcinoma cell line (F3II). Results obtained 
after treatment with AZT (600 µM) for 15 passages confirmed 
the inhibitory effect on telomerase. Regarding extratelomeric 
activities, our results showed a decrease of 64, 38 and 25% 
in the transcription of c-Myc, Cyc-D1 and TERT, respectively 
(p<0.05) after AZT treatment. Furthermore, we found an effect 
on cell migration, reaching an inhibition of 48% (p<0.05) and 
a significant passage-dependent increase on cell doubling 
time during treatment. Finally, we evaluated the effect on cell 
cycle, obtaining a decline in G0/G1 in AZT-treated cells. These 
results allow us to postulate that AZT is not only an inhibitor 
of telomerase activity, but also a potential modulator of extra-
telomeric processes involved in cancer promotion.
Introduction
Most tumor cells have an unlimited replicative potential, 
mainly due to the presence of the active telomerase holoen-
zyme, showing it as an attractive target for cancer therapies. 
Telomerase is a ribonucleoprotein complex that adds telomeric 
sequences at the end of the chromosome, maintaining telomere 
length in tumor cells (1). The human holoenzyme telomerase is 
a ribonucleoprotein composed by a catalytic subunit, (hTERT) 
and an RNA component (hTR) which acts as a template for 
the addition of a short repetitive sequence d(TTAGGG)n in 
the 3' end of the telomeric DNA and species-specific acces-
sory proteins (2). Recently, it has been demonstrated that 
dyskerin binds to hTR, giving it the right conformation to 
ensemble with hTERT, being essential for the conformation 
of an active enzyme. Additionally N0P10, NHP2 and GAR1 
proteins provide greater stability to the complex while pontin 
and reptin are two closed ATPases necessary for the stability 
of dyskerin and hTR in vivo (3).
3'-Azido-2',3'-dideoxythymidine [azidothymidine (AZT) 
or zidovudine] is a thymidine analogue used in the treatment 
of AIDS since it competitively inhibits reverse transcriptase 
(RT). The main component of telomerase, hTERT, is a cata-
lytically active RT structurally similar to HIV-1 RT (4). Such 
similarity prompted studies on the feasibility of telomerase 
inhibition with a known inhibitor of viral RT such as AZT. 
In our laboratory, it was demonstrated for the first time that 
AZT is incorporated preferentially in the telomeric DNA of 
CHO cells (5). Few years later, we demonstrated the inhibitory 
action of AZT on telomere dynamics (6), and later we found 
that the cells of an experimental mammary carcinoma (F3II) 
treated for prolonged periods with no cytotoxic doses of AZT 
enter into senescence and programmed cell death (7).
Besides its role in telomere maintenance (canonical function), 
TERT has additional functions. They are related, with regulation 
of cell behavior, but in a telomeric-independent manner (non-
canonical). For instance, TERT can function as a transcriptional 
modulator of the signaling pathway Wnt/β-catenin (8,9). In this 
manner, TERT acts as a cofactor in a transcriptional complex 
of β-catenin through interactions with a chromatin remodelling 
protein, allowing regulation of target genes of this pathway (10). 
Good examples are cyclin-D1 (Cyc-D1), which plays a key role 
in cell cycle progression (11) and c-Myc with a direct link to cell 
growth, differentiation and apoptosis (12).
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In order to increase insight into the mechanism of action 
of AZT as an anticancer drug, the present study analyzed the 
possible effects of AZT treatment on the transcription of genes 
involved in the signaling pathway Wnt/β-catenin (TERT, 
cMyc and Cyc-D1) its effect on telomerase activity, cytoskel-
eton structure, tumor cell migration and cell cycle in a murine 
mammary adenocarcinoma cell model (F3II).
Materials and methods
Cell line and culture conditions. The mammary carcinoma 
cell line F3II is a highly aggressive and metastatic variant, 
established from a clonal subpopulation of a spontaneous 
hormone-independent BALB/c mouse mammary tumor (13). 
Cells were grown in Dulbecco's modified Eagle's medium 
(DMEM) (Life Technologies) supplemented with 10% 
heat-inactivated fetal bovine serum (FBS), 2 mM glutamine 
and 80 µg/ml gentamicin at 37˚C in 5% CO2 atmosphere. Cell 
cultures were routinely subculture by trypsinization using 
standard procedures.
Cell proliferation assay. Cells (1x104) were plated in 96-well 
plates, and then treated with different concentration of AZT 
(50-2,000 µM) for 72 h. Cell growth was measured by colo-
rimetric MTT assay (Sigma). The concentration producing 
50% inhibition (IC50) was determined by non-linear regression 
function of GraphPad Prism 6®. Results shown correspond 
to the average of three individual experiments. Furthermore, 
in order to demonstrate that AZT was not toxic at this dose, 
another control with AZT in parallel with the untreated 
control cells was added on the experiments on doubling time, 
telomerase activity and cell migration.
RNA extraction and cDNA synthesis. For each treatment, 
total RNA was isolated by extraction with TRIzol reagent 
(Life Technologies) according to the manufacturer's specifica-
tions. cDNA synthesis was performed using SuperScript III 
First-Strand Synthesis System (Life Technologies) from ~1 µg 
of total RNA with oligonucleotide dT18 (Life Technologies) 
according to the manufacturer's instructions. All cDNA 
samples were normalized by quantification at 260 nm in 
NanoDrop 1000 (Thermo).
Analysis of Cyc-D1, c-Myc and TERT transcription by 
real-time PCR. Specific primers were designed for each 
target using the Primer Express® Software Version 3.0 
(Life Technologies). All primers designed presented efficiency 
values between 90 and 100%, and suitable dynamic ranges, 
allowing its proper use. The assays were carried out on 
One-Step Real-Time PCR System (Life Technologies) using 
SYBR-Green detection reagent (Life Technologies). β-actin 
transcript was used as a loading control. Once optimized all 
the parameters for RT-qPCR, the analysis of transcriptional 
expression was carried out by the ΔΔCt method.
Determination of telomerase activity. Telomerase activity 
was determined by TRAP assay, using RT-qPCR method with 
SYBR-Green (StepOne™ System equipment). The growing 
tumor cells were harvested and washed once with phosphate-
buffered saline (PBS). Cells (2x106) were transferred to 1.5 ml 
conical tubes and centrifuged for 8 min at 450 x g. The pellet was 
lysed with 200 µl of buffer CHAPS (RNaseOUT + Protease 
Inhibitor), quantified and stored at -20˚C until use.
Actin staining. Control and AZT-treated cells were grown in 
glass coverslips in serum-free DMEM. Cells were fixed in 4% 
formaldehyde in PBS and stained with Alexa Fluor 555-conju-
gated phalloidin (Molecular Probes, Life Technologies) 
following the manufacturer's instructions. Images were recorded 
by an inverted fluorescence microscope (Nikon Eclipse T2000). 
Alternatively, a quantitative analysis in which the intensity of 
emitted fluorescence of the same reagent was determined by 
measurement in a fluorometer Synergy HT (BioTek).
Cell migration. Cell migration was measured using an in vitro 
wound healing assay as previously described (14). Briefly, 
in vitro ‘scratch̓ wounds were created by scraping confluent 
F3II (controls and 5, 10 and 15 AZT passages) monolayers 
with a sterile pipette tip. After 16 h incubation in DMEM with 
10% FBS in the presence or absence of AZT, cells were fixed 
and stained. Ten random micrographs/well were obtained and 
migration area was quantified using NIS-Elements 3.0 (Nikon) 
software.
Cell cycle. For cell cycle analysis by flow cytometry, cells were 
washed and incubated in serum-free DMEM for synchroni-
zation for 24 h. Cells, both control and treated with AZT 
600 µM for passages 5, 10 and 15 were cultured, trypsinized 
and centrifuged at 450 x g. Cells were fixed in 70% methanol 
in PBS and stained with propidium bromide (1 mg/ml) 
(Life Technologies). Cell cycle progression was analyzed 
in a BD FACSCalibur™ (BD Biosciences) flow cytometer. 
Before recording 10,000 events, the verification of the doublet 
discrimination function of the flow cytometer was performed 
using DNA QC Particles kit (BD Biosciences).
Doubling time assay. Cells (1,5x104) treated with AZT 600 µM 
for 5, 10 and 15 passages were plated in 12-well plates. After 
incubation with DMEM 10% FBS and AZT treatment for 24, 
48, 72 and 96 h, each plate was stained and fixed by 0.5% 
violet crystal 20% methanol, resuspended in 500 µl of ethanol: 
acetic acid (3:1) and measured at 570 nm. A growth curve was 
built, where the 100% was defined as the 24 h value for each 
condition.
Statistical analysis. All data are presented as the mean ± SD. 
Significant differences were determined by one-way 
ANOVA with Dunnett contrast, and two-way ANOVA with 
a Bonferroni's multiple comparisons test. The analyses 
were performed by GraphPad Prism 6 software (GraphPad 
Software, La Jolla, CA, USA). The criterion for a statistical 
significance is p<0.05.
Results
Effect of AZT on cell viability. In order to confirm the effect of 
AZT on cell viability, we determined the IC50 of this molecule 
for F3II cell line, obtaining a value of 1,195±37 µM. Regarding 
the data, we determined 600 µM as the treatment dose, equiva-
lent to an IC25 value.
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Determination of telomerase activity. Telomerase activity 
significantly decreased and was evaluated progressively during 
the period. Telomerase activity dropped 26.22% (p<0.05), 
36.27% (p<0.01) and 45.08% (p<0.001) after 5, 10 and 
15 passages with AZT, respectively (Fig. 1). In this manner, 
corroborating the inhibitory function of AZT on telomerase 
activity.
Analysis of TERT, c-Myc and Cyc-D1 transcription. We quan-
tified relative expression by ΔΔCt method of the expression of 
TERT, Cyc-D1 and c-Myc genes, where β-actin gene was used 
as endogenous loading control.
We determined the relative expression of TERT and 
confirmed its expression was influenced by the treatment, in 
a passage-dependent manner. After 5 passages TERT expres-
sion decreased by 17.1% (p<0.05), at 10 passages, expression 
reduced by 20.28% (p<0.05) and at the end of treatment had 
declined by 30.91% (p<0.05) (Fig. 2C).
Regarding the expression of Cyc-D1 in cells treated with 
AZT, we found a passage-dependent decrease. After 5, 10 
and 15 passages, we observed a decline of 24.52% (p<0.05), 
30.87% (p<0.05) and 38.24% (p<0.01), respectively (Fig. 2A).
Analyzing c-Myc we found a more pronounced decline, 
reaching 34.14% (p<0.01), 43.85% (p<0.001) and 64.2% 
(p<0.01) of inhibition at 5, 10 and 15 treated passages, respec-
tively (Fig. 2B).
Anti-migratory effect of AZT. Due to the changes in the tran-
scription of c-Myc, we expected an effect on cell migration. 
Using the wound assay, we analyzed this effect on cells treated 
with 600 µM AZT for 5, 10 and 15 passages. After 5 passages 
significant effects on cell migration were not seen. However, 
after 10 and 15 passages, the invaded area decreased 31% 
(p<0.01) and 47.79% (p<0.01) (Fig. 3).
Evaluation of the actin cytoskeleton. Control cells showed 
normal actin fibers in most cells with intense fluorescence 
on the whole cell area (Fig. 4A). At passage 5 treated cells 
exhibited some fluorescence in the cell periphery and also 
actin fibers like the untreated ones (Fig. 4B). Changes in the 
cytoskeleton were evident after passage 10. Cells had less actin 
fibers whereas a greater amount of cortical fluorescence was 
observed (Fig. 4C). Similar effect was observed at passage 15, 
where the fluorescence was much more diffuse, actin fibers 
were no longer present, and low fluorescence intensity was 
observed in the cytoplasm (Fig. 4D).
Effect of AZT on growth and the cell cycle. Cell populations 
were without significant differences throughout all phases of 
the cell cycle (Fig. 5). There were slight differences in the 
cell proportions in each cell cycle stage, but along the treat-
ment, cells growth rate was not the same between control and 
treated cells. Once discarded effects on cell cycle arrest, we 
proceeded to determine doubling times of cells during treat-
ment with AZT. Doubling time determination was performed 
by cell counting after 24, 48, 72 and 96 h. The F3II cell line 
in normal growth presented a doubling time of 22.82 h. At 
passage 5 after treatment, the doubling time was 43.13 h, at 
10 passages was 56.21 h, and finally after 15 passages was 
67.22 h (Fig. 6). This information demonstrates a clear and 
progressive increase in the doubling time, in relation with the 
number of passages treated with AZT.
Figure 2. Determination of gene expression of Cyc-D1, c-Myc and TERT. Relative quantitation was performed by qPCR of the target genes using as charge 
control gene β-actin. Values represent mean ± SEM (n=6; *p<0.05 and **p<0.01 vs. the control) (ANOVA with Dunnett contrast). Asterisks are indication of 
significant difference in comparison with untreated cells (fold difference, 0).
Figure 1. Determination of telomerase activity by qPCR. Quantification was 
performed by real-time PCR with specific primers using as template protein 
lysates obtained from the treated cells, at different passages (P). Values rep-
resent mean ± SEM (n=6, *p<0.05 and **p<0.01 vs. the control) (ANOVA with 
Dunnett contrasted).
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Figure 3. Evaluation of the effect of AZT on cell migration. Evaluated by scratch wound. Crystal violet staining, magnification x200. Quantification was 
performed using the NIS-Elements 3.0 software. Values represent mean ± SEM (n=6; *p<0.05 and **p<0.01 vs. the control) (ANOVA with Dunnett contrast).
Figure 6. Analysis of AZT treatment on cell doubling time. Cells (15,000/well) 
were seeded in 12-wells. Plates with crystal violet and reading at 570 nm 
revealed every 24 for 96 h. A growth curve given as 100% measured at 24 h 
for each treatment was built. Statistical analysis was performed by comparing 
the non-linear adjustment curves through its parameters.
Figure 4. Evaluation of the effect of AZT on the cytoskeleton. Changes in the actin cytoskeleton (phalloidin and DAPI staining) was assessed by fluorescence 
microscopy. Magnification, x1,000.
Figure 5. Effect of AZT on the cell cycle. The assay was performed by 
flow cytometry with propidium iodide staining (BD FACSCalibur). Events 
(10,000)/sample were acquired.
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Discussion
3-Azido-2,3-dideoxythymidine [azidothymidine (AZT) or 
zidovudine] was the first reported telomerase inhibitor. The 
mechanism of AZT antitumor action still remains elusive. AZT 
is able to transform an immortal cell in a mortal one. It has 
been said that this was due to its action as a chain terminator. 
Although the experimental results support this view, AZT 
by itself could produce a specific antitumor action by other 
means, independently of its action as a telomerase inhibitor. 
Lately, a number of non-telomeric telomerase functions have 
been described. For instance, TERT, the main component 
of telomerase, allows the regulation of target genes of the 
signaling pathway Wnt/β-catenin (15), highlighting Cyc-D1 
and C-myc. In the present study, we intend to demonstrate 
that canonical and non-canonical functions of telomerase are 
affected by AZT in the same cell line and with the same dose 
integrating the different mechanisms of action underlying the 
role of AZT in tumor biology (16).
Chronic treatment with a dose of 600 µM of AZT progres-
sively decreased the telomerase activity along 15 passages 
in F3II cell line without effects on cell viability. Our group 
was the first to find this effect using 800 µM (6). Later, many 
other authors confirmed this finding. In the present study 
we found at 600 µM, that expression levels of TERT were 
significantly reduced through the passages evaluated. Given 
that, it has been reported that TERT acts as a modulator of 
β-catenin/BRG1 transcriptional complex, which acts on target 
genes of the signaling pathway Wnt/β-catenin, it is evident to 
expect that a decrease in the expression levels of TERT nega-
tively impacts on expression of C-Myc and Cyc-D1 genes. Our 
results revealed a continuing decline, corresponding with the 
amount of passages, in the expression of both genes, reaching 
expression levels up to two-fold reduction for C-Myc and one-
fold reduction to Cyc-D1. This result allows us to infer that 
the decline in TERT expression due to treatment with AZT, 
could be affecting its role as a positive regulator of these 
genes, coinciding with studies in the literature who analyze 
knockdown models of TERT (17). Ji et al demonstrated in 
2005 that intermittent treatment with AZT initially suppressed 
hTERT and then c-Myc. Similar results were found by Jin et al 
in 2012 (18).
Regarding variations in Cyc-D1 after AZT treatment, 
we found a passage-dependent decrease reaching 38.24% at 
15 passages. Downregulating expression of Cyc-D1 is a clear 
marker of changes or modulation in the cell cycle, being the 
protein which is required for G1/S cell cycle progress. The 
decrease of this factor represents a cycle arrest in phase 
G0/G1 cell cycle. Due to the evidence collected regarding 
the expression of Cyc-D1, cell cycle analysis was performed 
by flow cytometry. As a result of this assay, we determined 
there was no such arrest. Similarly, Datta et al showed that 
long-term AZT-treated MT-2 cells arrest in all phases of the 
cell cycle (19). Fang et al found that cyclin-A was increased 
at early times after AZT treatment cyclin-dependent kinase 1 
was decreased at later time points, while it was found that 
AZT-treated compared to untreated mice downregulated 
Cyc-D2 (p=0.0003) (20). However, some authors have found 
different results in other models. Olivero et al found that 
AZT induced an upregulation of Cyc-D1 accompanied by a 
downregulation of the Cyc-D1-associated inhibitors P18 and 
P57 (21). Regarding the decline found in a Cyc-D1 expression 
after treatment, it is important to highlight the key role played 
by this protein in cell cycle entry. The first approximation 
of this effect was based on the impact it would have on this 
process expecting an increase in the proportion of cells in 
state G0/G1 (22). The results obtained on the cell cycle assay 
did not allow us to observe this phenomenon, showing a 
decrease in the proportion of cells in G1 phase; a constant 
proportion of cells in S phase and an increased G2/M phase at 
the long-term AZT-treated cells. One possible interpretation 
for this observed phenomenon could be based on the fact 
that treatment with AZT increased levels of p21 mRNA (23). 
This protein is known for its role in controlling the cell cycle 
through inhibition of complex E/cdk2 and A/cdk2, being able 
to stop the progression of the cell cycle. In addition to this, 
during S phase, it is also able to inhibit CDK1-cyclin-A and 
CDK2-cyclin-A, which are required for progression through 
S and G2, respectively (24). Another possible alternative to 
this alteration of the cell cycle, which also involves p21, is the 
relationship between this protein and c-Myc, being the last one 
presented as a repressor of p21 expression. At lower levels of 
expression of c-Myc, p21 levels increase, leading the regulation 
of different cell cycle cyclins. These facts could explain the 
differences between the cell amount in each phases of the cell 
cycle observed after treatment (25).
In addition, has been reported that c-Myc has an important 
role in what concerns mitosis and DNA replication, being a 
regulator of the target genes Cdc6, Cdt1, MCM3, 4 and 5 and 
other genes associated with this processes (22). This explana-
tion coincides with was observed in our results of doubling 
time performed on cells at different passages (0, 5, 10 and 15), 
where the average doubling time is increased significantly 
along passages, suggesting that the AZT could impact in 
mitosis and duplication of the treated cells.
Chronic treatment with AZT decreases cell migra-
tion, and substantially modifies the reorganization of actin 
cytoskeleton, finding passage-dependent response in a high 
aggressiveness model as F3II. The literature suggests that 
there is a link between the expression of c-Myc and invasive 
phenotype of the cell that correlates high expression of this 
gene with increased migratory ability (26). Our results agree 
with this evidence, observing that along the treatment the 
expression of this gene is diminished as well as migration and 
actin filament formation, indicating that the treated cells have 
an epithelial phenotype which it was associated with a less 
aggressive profile. This link between c-Myc, cytoskeleton and 
migration is described in literature and it was related to the 
effect of c-Myc on signaling via RhoA/ROCK, which is highly 
related to the regulation of epithelial-mesenchymal transition, 
motility cell signaling and cytoskeletal organization (27). 
Focussing on the results obtained, we can postulate that AZT 
treatment has an effect on cell migration, probably through the 
regulation of c-Myc and TERT by AZT, leading tumor cells to 
a less aggressive phenotype, being a remarkable event in the 
field of extratelomerics activities. To the best of our knowledge 
no previous study has focused on cell migration after AZT 
treatment.
In conclusion, the results and information presented here, 
are intended to clarify and contribute to the study of how 
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AZT exerts its antitumoral effect. Telomerase stands at the 
crossroads of multiple signaling pathways and its upregula-
tion/reactivation leads to the modulation of critical cellular 
processes, including gene expression and metabolism. 
Understanding AZT antitumoral action is of utmost impor-
tance, even more since the recent report of Bhushan and Kush 
on the pharmocophoric studies of anti-telomerase drugs. They 
found that AZT and few non-nucleoside HIV-RTIS have 
exquisite selectivity, not requiring bioactivation by kinases 
to triphosphate and not attaching into growing DNA chain. 
Instead, binding to allosteric site of the reverse transcriptase 
that is distinct from the substrate binding site. Therefore, they 
bind reverse transcriptase near catalytic site and instantly 
denature it by the non-competitive mechanism (28).
Although most of the described effects were known, this is 
the first time that the mentioned variables were analyzed after 
treatment with AZT using the same treatment, in the same cell 
line and at the same time, providing evidence that they are not 
interfering among them, and that AZT inhibitory action may 
be due to a mix of canonical and non-canonical effects.
Even knowing that more experiments are needed, we 
started a differential display study with cells treated or not 
with AZT. Preliminary results point toward the described dual 
effect.
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